Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 248


The E2F4 prognostic signature is also predictive of the pathological response of breast cancer to chemotherapy.

Bertucci F, Finetti P, Birnbaum D.

Breast Cancer Res. 2015 Apr 10;17(1):54. doi: 10.1186/s13058-015-0559-2. No abstract available.


NGF-induced TrkA/CD44 association is involved in tumor aggressiveness and resistance to lestaurtinib.

Aubert L, Guilbert M, Corbet C, Génot E, Adriaenssens E, Chassat T, Bertucci F, Daubon T, Magné N, Le Bourhis X, Toillon RA.

Oncotarget. 2015 Mar 25. [Epub ahead of print]


Guideline sheets on the side effects of anticancer drugs are useful for general practitioners.

Rouge-Bugat ME, Lassoued D, Bacrie J, Boussier N, Delord JP, Oustric S, Bauvin E, Lapeyre-Mestre M, Bertucci F, Grosclaude P.

Support Care Cancer. 2015 Mar 27. [Epub ahead of print]


Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.

Pautier P, Floquet A, Chevreau C, Penel N, Guillemet C, Delcambre C, Cupissol D, Selle F, Isambert N, Piperno-Neumann S, Thyss A, Bertucci F, Bompas E, Alexandre J, Collard O, Lavau-Denes S, Soulié P, Toulmonde M, Le Cesne A, Lacas B, Duffaud F; French Sarcoma Group.

Lancet Oncol. 2015 Apr;16(4):457-64. doi: 10.1016/S1470-2045(15)70070-7. Epub 2015 Mar 18.


Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.

Jansen MP, Sas L, Sieuwerts AM, Van Cauwenberghe C, Ramirez-Ardila D, Look M, Ruigrok-Ritstier K, Finetti P, Bertucci F, Timmermans MM, van Deurzen CH, Martens JW, Simon I, Roepman P, Linn SC, van Dam P, Kok M, Lardon F, Vermeulen PB, Foekens JA, Dirix L, Berns EM, Van Laere S.

Mol Oncol. 2015 Mar 4. pii: S1574-7891(15)00030-7. doi: 10.1016/j.molonc.2015.02.006. [Epub ahead of print]


Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.

Allensworth JL, Evans MK, Bertucci F, Aldrich AJ, Festa RA, Finetti P, Ueno NT, Safi R, McDonnell DP, Thiele DJ, Van Laere S, Devi GR.

Mol Oncol. 2015 Feb 21. pii: S1574-7891(15)00031-9. doi: 10.1016/j.molonc.2015.02.007. [Epub ahead of print]


Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group.

Le Cesne A, Ray-Coquard I, Duffaud F, Chevreau C, Penel N, Bui Nguyen B, Piperno-Neumann S, Delcambre C, Rios M, Chaigneau L, Le Maignan C, Guillemet C, Bertucci F, Bompas E, Linassier C, Olivier T, Kurtz JE, Even C, Cousin P, Yves Blay J; French Sarcoma Group.

Eur J Cancer. 2015 Apr;51(6):742-50. doi: 10.1016/j.ejca.2015.01.006. Epub 2015 Feb 23.


Interruption versus continuation of trabectedin in patients with soft-tissue sarcoma (T-DIS): a randomised phase 2 trial.

Cesne AL, Blay JY, Domont J, Tresch-Bruneel E, Chevreau C, Bertucci F, Delcambre C, Saada-Bouzid E, Piperno-Neumann S, Bay JO, Mir O, Ray-Coquard I, Ryckewaert T, Valentin T, Isambert N, Italiano A, Clisant S, Penel N.

Lancet Oncol. 2015 Mar;16(3):312-9. doi: 10.1016/S1470-2045(15)70031-8. Epub 2015 Feb 11.


Prognostic and predictive value of PDL1 expression in breast cancer.

Sabatier R, Finetti P, Mamessier E, Adelaide J, Chaffanet M, Ali HR, Viens P, Caldas C, Birnbaum D, Bertucci F.

Oncotarget. 2015 Mar 10;6(7):5449-64.


BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients.

Laroche-Clary A, Chaire V, Le Morvan V, Neuville A, Bertucci F, Salas S, Sanfilippo R, Pourquier P, Italiano A.

Br J Cancer. 2015 Feb 17;112(4):688-92. doi: 10.1038/bjc.2014.624. Epub 2015 Jan 20.


[Systemic treatments of inflammatory breast cancer: an overview].

Monneur A, Bertucci F, Viens P, Gonçalves A.

Bull Cancer. 2014 Dec;101(12):1080-8. doi: 10.1684/bdc.2014.2014. Review. French.


The off-label use of targeted therapies in sarcomas: the OUTC'S program.

Eberst L, Cropet C, Le Cesne A, Pautier P, Penel N, Adenis A, Chevreau C, Bay JO, Collard O, Cupissol D, Duffaud F, Gentet JC, Piperno-Neumann S, Marec-Berard P, Bompas E, Thyss A, Chaigneau L, Cassier P, Bertucci F, Blay JY, Ray-Coquard I.

BMC Cancer. 2014 Nov 24;14:870. doi: 10.1186/1471-2407-14-870.


New insights into the role of the pharyngeal jaw apparatus in the sound-producing mechanism of Haemulon flavolineatum (Haemulidae).

Bertucci F, Ruppé L, Van Wassenbergh S, Compère P, Parmentier E.

J Exp Biol. 2014 Nov 1;217(Pt 21):3862-9. doi: 10.1242/jeb.109025.


TNFRSF11B gene polymorphisms increased risk of peripheral arterial occlusive disease and critical limb ischemia in patients with type 2 diabetes.

Biscetti F, Porreca CF, Bertucci F, Straface G, Santoliquido A, Tondi P, Angelini F, Pitocco D, Santoro L, Gasbarrini A, Landolfi R, Flex A.

Acta Diabetol. 2014 Dec;51(6):1025-32. doi: 10.1007/s00592-014-0664-1. Epub 2014 Oct 17.


Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.

Vita M, Tisserand JC, Chauvot de Beauchêne I, Panel N, Tchertanov L, Agopian J, Mescam-Mancini L, Fouet B, Fournier B, Dubreuil P, Bertucci F, De Sepulveda P.

JAMA Dermatol. 2014 Dec;150(12):1345-9.


Effect on survival of local ablative treatment of metastases from sarcomas: a study of the French sarcoma group.

Falk AT, Moureau-Zabotto L, Ouali M, Penel N, Italiano A, Bay JO, Olivier T, Sunyach MP, Boudou-Roquette P, Salas S, Le Maignan C, Ducassou A, Isambert N, Kalbacher E, Pan C, Saada E, Bertucci F, Thyss A, Thariat J; Groupe Sarcome Francais-Groupe D'etude Des Tumeurs Osseuses.

Clin Oncol (R Coll Radiol). 2015 Jan;27(1):48-55. doi: 10.1016/j.clon.2014.09.010. Epub 2014 Oct 7.


Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization.

Sabatier R, Finetti P, Guille A, Adelaide J, Chaffanet M, Viens P, Birnbaum D, Bertucci F.

Mol Cancer. 2014 Oct 2;13:228. doi: 10.1186/1476-4598-13-228.


The functional landscape of Hsp27 reveals new cellular processes such as DNA repair and alternative splicing and proposes novel anticancer targets.

Katsogiannou M, Andrieu C, Baylot V, Baudot A, Dusetti NJ, Gayet O, Finetti P, Garrido C, Birnbaum D, Bertucci F, Brun C, Rocchi P.

Mol Cell Proteomics. 2014 Dec;13(12):3585-601. doi: 10.1074/mcp.M114.041228. Epub 2014 Oct 2.


EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.

Bertucci F, Finetti P, Viens P, Birnbaum D.

Cancer Lett. 2014 Dec 1;355(1):70-5. doi: 10.1016/j.canlet.2014.09.014. Epub 2014 Sep 10.


Poly(ADP-ribose) polymerase 1 (PARP1) overexpression in human breast cancer stem cells and resistance to olaparib.

Gilabert M, Launay S, Ginestier C, Bertucci F, Audebert S, Pophillat M, Toiron Y, Baudelet E, Finetti P, Noguchi T, Sobol H, Birnbaum D, Borg JP, Charafe-Jauffret E, Gonçalves A.

PLoS One. 2014 Aug 21;9(8):e104302. doi: 10.1371/journal.pone.0104302. eCollection 2014.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk